Jakarta – State-owned pharmaceutical business PT Kimia Farma has said it is producing and distributing three versions of therapeutic COVID-19 drugs azithromycin, favipiravir, and remdesivir.
” Kimia Farma is producing azithromycin tablets, which are being produced by a total of 33 business in Indonesia, with 19 of the business producing generic azithromycin, including Kimia Farma,” said chairman of PT Kimia Farma, Verdi Budidarmo, at a conference with Commission VI of your home of Representatives, accessed practically from Jakarta on Wednesday.
The company has distributed at least 58 thousand boxes of azithromycin because June 2021, with each box including 20 tablets, he disclosed.
” This month, we will disperse almost six million tablets and in the following months,” he added.
Offering information on the distribution chain of the drug, he stated an overall of 1,233 PT Kimia Farma drug stores situated in different areas are among those equipping the drug presently.
PT Kimia Farma is likewise producing favipiravir and the business is expecting to enhance production to seven million tablets by July 23, 2021, Budidarmo informed.
He stated the drug has been cleared for emergency use by the Food and Drug Supervisory Agency (BPOM) and has been dispersed to numerous healthcare facilities through the business’s trading and distribution channel.
” Favipirapir is being produced by Kimia Farma. There are 6 domestic industries that are also producing it using practically all imported materials,” he included.
The state-owned pharmaceutical business is also aiming to satisfy the public need for the restorative drug remdesivir, Budidarmo stated.
” There are presently seven pharmaceutical markets in Indonesia that are importing the drug, among which is Kimia Farma,” he said.
Domestic demand for remdesivir injections, he continued, is intended to be satisfied by September this year.
PT Kimia Farma is associated with the domestic development of remdesivir injections, in addition to PT Phapros, Budidarmo informed including, the raw medicinal materials for the injections will be produced by a subsidiary of his business. (INE)
Associated news: Indofarma pursues attaining COVID-19 drug production target by Sept
Associated news: Hoarding of drugs, oxygen criminal offense versus humanity: ministry
EDITED BY INE
